Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06210971

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Exploratory Study on the Efficacy and Safety of Long-course Neoadjuvant Chemoradiation With Liposomal Irinotecan and Capecitabine Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer

Sponsor: Hebei Medical University Fourth Hospital

Conditions Rectal Cancer

Interventions Capecitabine Radiation threapy liposomal irinotecan

Updated 4 times since 2024 Last updated: Mar 10, 2025 Started: Feb 1, 2024 Primary completion: Feb 1, 2026 Completion: Jul 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06210971, this PHASE2 trial focuses on Rectal Cancer and remains actively recruiting participants. Sponsored by Hebei Medical University Fourth Hospital, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital

Data source: Hebei Medical University Fourth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shijiazhuang, China